Evidence Hub

P-286. Prevalence of Pseudomonas aeruginosa in patients with ICU-related respiratory Infections: A secondary analysis of the European Network for ICU-Related Respiratory Infections (ENIRRIs)

Cristian C. Serrano-Mayorga, Juan Olivella-Gómez, A. Torres, I. Martín-Loeches, L. F. Reyes

Open Forum Infectious Diseases, 2025

1,059 participants · 2 citations

Abstract

Abstract Background Microorganisms causing healthcare-associated infections are usually difficult to treat Gram-negative bacteria, making the empiric antibiotic selection challenging. Pseudomonas aeruginosa (PA) is a microorganism associated with hospital-acquired infections, and its rate of antimicrobial resistance has increased in the last ten years. However, the international prevalence of P. aeruginosa in ICU-Related Respiratory Infections (ICU-RRI) is unknown. This study aims to bridge this gap in the literature using a multicenter cohort study.Figure 1: Prevalence of Pseudomonas aeruginosa infection by countries Figure 1: Prevalence of Pseudomonas aeruginosa infection by countries for participants in the entire cohort (A) and bacterial microbiological Identification (B) Europe is shown in detail because of the high number of patients enrolled and the large number of participating countries. Methods This prospective cohort was conducted in 12 countries over two continents from 9th May 2016 until 16th August 2019. Characteristics and outcomes of VAP, VAT, ICU-HAP, HAP (i.e., patients transferred to the ICU without requiring invasive mechanical ventilation), and HAP that required invasive ventilation (VHAP) were collected. All patients were tested to find microbiological agents and their resistance phenotype. We assessed the prevalence of Pseudomonas aeruginosa ICU-RRI.Figure 2: Prevalence of Pseudomonas aeruginosa with antimicrobial resistance infection by countries…

How strong is the evidence?

Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,059 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free